Related Experiment Videos
Strontium ranelate in osteoporosis
1WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, Liège, Belgium. jyreginster@ulg.ac.be
Current Pharmaceutical Design
|August 13, 2002
Summary
Strontium ranelate enhances bone formation and reduces bone resorption, acting as a dual-action agent for osteoporosis treatment. Clinical studies show significant improvements in bone mineral density and fracture risk reduction with strontium ranelate.
Area of Science:
- Pharmacology and Bone Biology
- Osteoporosis Research
- Drug Development
Background:
- Strontium ranelate, a combination of ranelic acid and strontium, exhibits dual effects on bone metabolism.
- In vitro studies demonstrate its capacity to stimulate osteoblast activity and inhibit osteoclast function.
Purpose of the Study:
- To evaluate the efficacy and safety of strontium ranelate in improving bone mineral density (BMD) and reducing fracture risk in postmenopausal women with osteoporosis.
Main Methods:
- Conducted double-blind, placebo-controlled studies in postmenopausal women with osteoporosis.
- Administered varying daily doses of strontium ranelate (125 mg to 2 g) over 24 months.
- Assessed changes in lumbar and hip BMD, vertebral fracture incidence, and biochemical markers of bone turnover.
Main Results:
- Significant increases in lumbar, hip, and neck BMD were observed with strontium ranelate treatment compared to placebo.
- A reduction in new vertebral deformities was noted in patients receiving 2 g/day.
- Biochemical markers indicated suppressed bone resorption and increased bone formation.
Conclusions:
- Strontium ranelate demonstrates a favorable profile as a bone-forming and anti-resorptive agent for osteoporosis.
- It effectively increases BMD and reduces fracture risk without significant adverse effects.